PUTTINI, MIRIAM
 Distribuzione geografica
Continente #
NA - Nord America 1.226
EU - Europa 632
AS - Asia 127
AF - Africa 2
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 1
SA - Sud America 1
Totale 1.991
Nazione #
US - Stati Uniti d'America 1.205
DE - Germania 298
CN - Cina 93
SE - Svezia 77
UA - Ucraina 72
IT - Italia 60
BE - Belgio 30
GB - Regno Unito 27
CA - Canada 21
IE - Irlanda 16
DK - Danimarca 15
FI - Finlandia 15
IN - India 12
HK - Hong Kong 9
SG - Singapore 7
RU - Federazione Russa 6
IR - Iran 3
NL - Olanda 3
RO - Romania 3
AT - Austria 2
EU - Europa 2
FR - Francia 2
TR - Turchia 2
BR - Brasile 1
CH - Svizzera 1
EG - Egitto 1
ES - Italia 1
LU - Lussemburgo 1
MY - Malesia 1
MZ - Mozambico 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PT - Portogallo 1
RS - Serbia 1
Totale 1.991
Città #
Ann Arbor 370
Frankfurt am Main 229
Woodbridge 134
Chandler 96
Fairfield 92
Wilmington 85
Jacksonville 60
Ashburn 51
Houston 48
Dearborn 44
Seattle 33
Milan 31
Brussels 30
Cambridge 23
Nanjing 23
Princeton 20
Göttingen 18
Dublin 16
New York 15
Lachine 10
Shanghai 10
Fremont 9
Guangzhou 9
Altamura 8
Hong Kong 8
Lawrence 8
Nanchang 8
Shenyang 8
Beijing 6
Fürstenwalde 6
Pune 6
Tianjin 6
Edmonton 5
Helsinki 5
Kiev 5
Toronto 5
Gorgonzola 4
Jinan 4
Kunming 4
Philadelphia 4
Andover 3
Hanover 3
Jiaxing 3
London 3
Boardman 2
Changsha 2
Falls Church 2
Hefei 2
Huizen 2
Langfang 2
Monmouth Junction 2
Mountain View 2
Nürnberg 2
Redmond 2
Rovellasca 2
San Diego 2
Trieste 2
Zanjan 2
Adliswil 1
Americana 1
Amsterdam 1
Auckland 1
Belgrade 1
Buffalo 1
Cairo 1
Central 1
Chicago 1
Duncan 1
Hangzhou 1
Kuala Lumpur 1
Leawood 1
Levico Terme 1
Lisbon 1
Luxembourg 1
Madrid 1
Norwalk 1
Oslo 1
Otley 1
Ottawa 1
Perugia 1
Piemonte 1
Ripalta Cremasca 1
Robbio 1
Sacramento 1
San Francisco 1
San Mateo 1
Stockholm 1
Trento 1
Walnut 1
Wuhan 1
Zhangzhou 1
Totale 1.629
Nome #
Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib 311
Imatinib Long-Term Effects Study: Global Independent Assessment of Imatinib in Chronic Myeloid Leukemia: Results At 8 Years 308
Imatinib long term effects study: three years of follow-up and assessment 272
Characterization of compound 584, an Abl kinase inhibitor with lasting effects 265
In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells 212
NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma 196
Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy 182
Inhibition of RET tyrosine kinase by SU5416 167
NPM/ALK co-localizes with, and phosphorylates PSF and other RNA-binding proteins 118
In vitro and in vivo activity of SKI-606, a novel Abl/Src inhibitor, against imatinib resistant BCR-ABL plus neoplastic 113
Totale 2.144
Categoria #
all - tutte 4.133
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.133


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019143 0 0 0 0 0 11 16 8 35 16 27 30
2019/2020458 39 31 34 28 39 51 75 37 49 35 35 5
2020/2021446 13 21 56 49 47 100 40 49 47 19 2 3
2021/2022149 5 12 18 8 7 17 7 4 5 18 15 33
2022/2023346 32 98 37 30 16 39 1 24 16 2 21 30
2023/2024260 38 50 48 49 46 29 0 0 0 0 0 0
Totale 2.144